Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 1992

Primary Completion Date

July 31, 2001

Study Completion Date

January 31, 2006

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

DRUG

cyclophosphamide

Trial Locations (15)

10029

Mount Sinai Medical Center, NY, New York

11030

CCOP - North Shore University Hospital, Manhasset

13210

State University of New York - Upstate Medical University, Syracuse

21201

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

38103

University of Tennessee, Memphis Cancer Center, Memphis

52242

University of Iowa Hospitals and Clinics, Iowa City

60637

University of Chicago Cancer Research Center, Chicago

63110

Barnes-Jewish Hospital, St Louis

65203

Ellis Fischel Cancer Center - Columbia, Columbia

89106

CCOP - Southern Nevada Cancer Research Foundation, Las Vegas

01655

University of Massachusetts Memorial Medical Center, Worcester

03756

Norris Cotton Cancer Center, Lebanon

27104-4241

CCOP - Southeast Cancer Control Consortium, Winston-Salem

27157-1082

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem

02903

Rhode Island Hospital, Providence

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00002501 - Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter